Abstract
In the era of personalized and precision medicine, the importance of next-generation sequencing in metastatic breast cancer has been increasingly recognized. This case highlights one such example in which a patient with heavily pretreated, hormone receptor-positive metastatic breast cancer was discovered to have a PIK3CA mutation and started on a PIK3 inhibitor with an exceptional response. This patient had been facing a visceral crisis with diffuse liver metastasis and hyperbilirubinemia. Alpelisib was able to achieve rapid disease control within a matter of weeks with clinical and objective laboratory improvement. To date, there has been no published data regarding the safety of alpelisib in patients with elevated bilirubin and this case report lends support to safety and efficacy in this situation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
